Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Status:
Terminated
Trial end date:
2018-01-31
Target enrollment:
Participant gender:
Summary
A lead-in cohort of ~20 patients with primary or secondary myelofibrosis previously treated
with 1 or more Janus kinase inhibitors enrolled to single-agent glasdegib to evaluate safety
and tolerability. Following the lead-in, a phase 2, double blind, 2-arm study, randomized 2:1
to oral single-agent glasdegib versus placebo in 201 patients resistant or intolerant to
ruxolitinib.